Literature DB >> 21908874

Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

Lilian Aly1, Sara Yousef, Sven Schippling, Ilijas Jelcic, Petra Breiden, Jakob Matschke, Robert Schulz, Silvia Bofill-Mas, Louise Jones, Viktorya Demina, Michael Linnebank, Graham Ogg, Rosina Girones, Thomas Weber, Mireia Sospedra, Roland Martin.   

Abstract

Progressive multi-focal leucoencephalopathy and progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome are caused by infection of the central nervous system with the JC polyoma virus. Both are complications of monoclonal antibody therapy in multiple sclerosis and other autoimmune diseases. Progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome can obscure the diagnosis of progressive multi-focal leucoencephalopathy and lead to severe clinical disability and possibly death. Different from progressive multi-focal leucoencephalopathy, in which demyelination results from oligodendrocyte lysis by JC virus in the absence of an immune response, tissue destruction in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome is caused by a vigorous immune response within the brain. The cells and mediators that are involved in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome are as yet poorly understood. We examined two patients with multiple sclerosis, who developed progressive multi-focal leucoencephalopathy and later progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome under natalizumab therapy. Due to initially negative JC viral deoxyribonucleic acid testing in the cerebrospinal fluid, a diagnostic brain biopsy was performed in one patient. Histopathology revealed brain inflammation characterized by a prominent T cell infiltrate (CD4(+)> CD8(+) T cells), but also B/plasma cells and monocytes. Despite very low JC viral load, both patients showed high intrathecal anti-JC virus antibodies. Brain-infiltrating CD4(+) T cells were studied regarding antigen specificity and function. CD4(+) T cells were highly specific for peptides from several JC virus proteins, particularly the major capsid protein VP1. T cell phenotyping revealed CD4(+) Th1 and bifunctional Th1-2 cells. The latter secrete large amounts of interferon-γ and interleukin-4 explaining the strong brain inflammation, presence of plasma cells and secretion of intrathecal anti-VP1 antibodies. The functional phenotype of brain-infiltrating JC virus-specific CD4(+) T cells was confirmed and extended by examining brain-derived JC virus-specific CD4(+) T cell clones. Our data provide novel insight into the pathogenesis of progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome and indicate that JC virus-specific CD4(+) T cells play an important role in both eliminating JC virus from the brain, but also in causing the massive inflammation with often fatal outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908874     DOI: 10.1093/brain/awr206

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  37 in total

1.  JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.

Authors:  Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik
Journal:  Ann Neurol       Date:  2014-06-10       Impact factor: 10.422

2.  Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

Review 3.  [MRI alterations in immunomodulation].

Authors:  K Guggenberger; H Urbach
Journal:  Nervenarzt       Date:  2018-08       Impact factor: 1.214

Review 4.  [Progressive multifocal leukoencephalopathy].

Authors:  C Warnke; M P Wattjes; O Adams; H-P Hartung; R Martin; T Weber; M Stangel
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

5.  Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

Authors:  Mireia Sospedra; Sven Schippling; Sara Yousef; Ilijas Jelcic; Silvia Bofill-Mas; Raquel Planas; Jan-Patrick Stellmann; Viktoria Demina; Paola Cinque; Robert Garcea; Therese Croughs; Rosina Girones; Roland Martin
Journal:  Clin Infect Dis       Date:  2014-09-11       Impact factor: 9.079

Review 6.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

7.  Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient.

Authors:  Aabha Oza; Michael P Rettig; Phil Powell; Kathryn O'Brien; David B Clifford; Julie Ritchey; Leah Gehrs; Julia Hollaway; Eugene Major; Todd A Fehniger; Christopher A Miller; Patrick Soon-Shiong; Amy Rock; John F DiPersio
Journal:  Blood Adv       Date:  2020-06-09

Review 8.  Immunology of progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Ilijas Jelcic; Wolfgang Faigle; Mireia Sospedra; Roland Martin
Journal:  J Neurovirol       Date:  2015-03-05       Impact factor: 2.643

Review 9.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

10.  JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.

Authors:  Shruti P Agnihotri; Xin Dang; Jonathan L Carter; Terry D Fife; Evelyn Bord; Stephanie Batson; Igor J Koralnik
Journal:  Neurology       Date:  2014-07-18       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.